Others titles
- New DDD Code 2022
- New ATC Update and Alterations
- New DDD Updates and Alterations
Keywords
- ATC Classification
- ATC/DDD
- ATC Alterations
- DDD Alterations
- New ATC
- New DDD
Defined Daily Dose Codes for 2018 to 2023
This dataset contains the Defined Daily Dose (DDD) 2018 to 2023. In order to measure drug use, it is important to have both a classification system and a unit of measurement. To deal with the objections against traditional units of measurement, a technical unit of measurement called the Defined Daily Dose (DDD) to be used in drug utilization studies was developed.
Get The Data
- ResearchNon-Commercial, Share-Alike, Attribution Free Forever
- CommercialCommercial Use, Remix & Adapt, White Label Log in to download
Description
In 1981, the WHO Regional Office for Europe recommended the ATC/DDD system for international drug utilization studies. In connection with this, and to make the methodology more widely used, there was a need for a central body responsible for co-ordinating the use of the methodology. The WHO Collaborating Centre for Drug Statistics Methodology was accordingly established in Oslo in 1982. The Centre is now located at the Norwegian Institute of Public Health. The Norwegian government funds the Centre.
In 1996, WHO recognized the need to develop use of the ATC/DDD system as an international standard for drug utilization studies. The Centre was therefore linked directly to WHO Headquarters in Geneva instead of the WHO Regional Office for Europe in Copenhagen. This was seen as important to allow close integration of international drug utilization studies and WHO’s initiatives to achieve universal access to needed drugs and rational use of drugs particularly in developing countries. Access to standardized and validated information on drug use is essential to allow audit of patterns of drug utilization, identification of problems, educational or other interventions and monitoring of the outcomes of the interventions.
When the decision on globalizing the ATC/DDD system was taken, the WHO Division of Drug Management and Policies established the WHO International Working Group for Drug Statistics Methodology. The WHO Collaborating Centre for Drug Statistics Methodology receives expert advice from the Working Group.
About this Dataset
Data Info
Date Created | 2017 |
---|---|
Last Modified | 2022-04-01 |
Version | 2022-04-01 |
Update Frequency |
Semiannual |
Temporal Coverage |
2018-2023 |
Spatial Coverage |
United States |
Source | John Snow Labs; WHO Collaborating Centre for Drug Statistics Methodology; |
Source License URL | |
Source License Requirements |
N/A |
Source Citation |
N/A |
Keywords | ATC Classification, ATC/DDD, ATC Alterations, DDD Alterations, New ATC, New DDD |
Other Titles | New DDD Code 2022, New ATC Update and Alterations, New DDD Updates and Alterations |
Data Fields
Name | Description | Type | Constraints |
---|---|---|---|
ATC_Code | A Unique Alpha Numeric Anatomical Therapeutic Chemical Code | string | - |
ATC_Level_Name | Anatomical Therapeutic Chemical Code Level Name | string | - |
New_DDD | New Rate of Defined Daily Dose. Various Sources are used to get the Best Overview of the Actual or Expected use of a Substance. | number | level : Ratio |
Unit | DDD Unit of measurement (g=gram, gm = milligram | string | - |
Administration_Route | Route of administration (O = oral, P = parenteral) | string | - |
Year | Year of Implementation | date | - |
Data Preview
ATC Code | ATC Level Name | New DDD | Unit | Administration Route | Year |
A03FA07 | itopride | 0.15 | g | O | 2022 |
B02BX08 | avatrombopag | 20.0 | mg | O | 2022 |
B06AX01 | crizanlizumab | 12.5 | mg | P | 2022 |
H02CA03 | ketoconazole | 0.6 | g | O | 2022 |
J05AG05 | rilpivirine | 15.0 | mg | P | 2022 |
J05AJ04 | cabotegravir | 10.0 | mg | P | 2022 |
J05AJ04 | cabotegravir | 30.0 | mg | O | 2022 |
J05AX29 | fostemsavir | 1.2 | g | O | 2022 |
L04AA41 | imlifidase | 17.5 | mg | P | 2022 |
L04AA43 | ravulizumab | 58.9 | mg | P | 2022 |